These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 33045023)

  • 1. Elevated miR-16-5p induces somatostatin receptor 2 expression in neuroendocrine tumor cells.
    Jo H; Park Y; Kim J; Kwon H; Kim T; Lee J; Pyun JC; Lee M; Yun M
    PLoS One; 2020; 15(10):e0240107. PubMed ID: 33045023
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroendocrine tumors--somatostatin receptor expression and somatostatin analog treatment.
    Janson ET; Oberg K
    Cancer Chemother Biol Response Modif; 2003; 21():535-46. PubMed ID: 15338762
    [No Abstract]   [Full Text] [Related]  

  • 3. The somatostatin analogue octreotide inhibits growth of small intestine neuroendocrine tumour cells.
    Li SC; Martijn C; Cui T; Essaghir A; Luque RM; Demoulin JB; Castaño JP; Öberg K; Giandomenico V
    PLoS One; 2012; 7(10):e48411. PubMed ID: 23119007
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Mechanisms and influence of octreotide-induced regulation of somatostatin receptor 2 on hepatocellular carcinoma.
    Hua YP; Yin XY; Peng BG; Li SQ; Lai JM; Liang HZ; Liang LJ
    Chemotherapy; 2009; 55(5):312-20. PubMed ID: 19590186
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical Evaluation of Response to Octreotide and Chemotherapy in High-Grade Malignant Neuroendocrine Tumors and Promising In Vitro Preclinical Results with Pasireotide.
    Doello K; Chico MA; Quiñonero F; Ortiz R; Prados J; Mesas C; Melguizo C
    Medicina (Kaunas); 2024 Jun; 60(7):. PubMed ID: 39064468
    [No Abstract]   [Full Text] [Related]  

  • 6. Differential regulation of somatostatin receptor type 2 (sst 2) expression in AR4-2J tumor cells implanted into mice during octreotide treatment.
    Froidevaux S; Hintermann E; Török M; Mäcke HR; Beglinger C; Eberle AN
    Cancer Res; 1999 Aug; 59(15):3652-7. PubMed ID: 10446977
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Gene expression of somatostatin receptor 4 predicts clinical outcome of patients with metastatic neuroendocrine tumors treated with somatostatin analogs.
    Slaby O; Sachlova M; Bednarikova M; Fabian P; Svoboda M; Vytopilova S; Valik D; Vyzula R
    Cancer Biother Radiopharm; 2010 Apr; 25(2):237-43. PubMed ID: 20423238
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Octreotide stimulates somatostatin receptor-induced apoptosis of SW480 colon cancer cells by activation of glycogen synthase kinase-3β, A Wnt/β-catenin pathway modulator.
    Wang S; Bao Z; Liang QM; Long JW; Xiao ZS; Jiang ZJ; Liu B; Yang J; Long ZX
    Hepatogastroenterology; 2013 Oct; 60(127):1639-46. PubMed ID: 24634935
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pasireotide and octreotide antiproliferative effects and sst2 trafficking in human pancreatic neuroendocrine tumor cultures.
    Mohamed A; Blanchard MP; Albertelli M; Barbieri F; Brue T; Niccoli P; Delpero JR; Monges G; Garcia S; Ferone D; Florio T; Enjalbert A; Moutardier V; Schonbrunn A; Gerard C; Barlier A; Saveanu A
    Endocr Relat Cancer; 2014 Oct; 21(5):691-704. PubMed ID: 25012983
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of the somatostatin receptor subtype-2 gene predicts response of human pancreatic cancer to octreotide.
    Fisher WE; Muscarella P; O'Dorisio TM; O'Dorisio MS; Kim JA; Doran TA; Sabourin CL; Schirmer WJ
    Surgery; 1996 Aug; 120(2):234-40; discussion 240-1. PubMed ID: 8751588
    [TBL] [Abstract][Full Text] [Related]  

  • 11. BIM-23A760, a chimeric molecule directed towards somatostatin and dopamine receptors, vs universal somatostatin receptors ligands in GH-secreting pituitary adenomas partial responders to octreotide.
    Jaquet P; Gunz G; Saveanu A; Barlier A; Dufour H; Taylor J; Dong J; Kim S; Moreau JP; Culler MD
    J Endocrinol Invest; 2005; 28(11 Suppl International):21-7. PubMed ID: 16625841
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Wnt/β-catenin modulating drugs regulate somatostatin receptor expression and internalization of radiolabelled octreotide in neuroendocrine tumor cells.
    Weich A; Rogoll D; Peschka M; Weich W; Pongracz J; Brand M; Fröhlich M; Serfling SE; Rowe SP; Kosmala A; Reiter FP; Meining A; Werner RA; Scheurlen M
    Nucl Med Commun; 2023 Apr; 44(4):259-269. PubMed ID: 36804512
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of novel somatostatin-dopamine chimeric drugs in 2D and 3D cell culture models of neuroendocrine tumors.
    Herrera-Martínez AD; van den Dungen R; Dogan-Oruc F; van Koetsveld PM; Culler MD; de Herder WW; Luque RM; Feelders RA; Hofland LJ
    Endocr Relat Cancer; 2019 Jun; 26(6):585-599. PubMed ID: 30939452
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Somatostatin receptor 2 in 10 different types of human non-neoplastic gastrointestinal neuroendocrine cells.
    Watanabe H; Fujishima F; Unno M; Sasano H; Suzuki T
    Pathol Res Pract; 2023 Apr; 244():154418. PubMed ID: 36989844
    [TBL] [Abstract][Full Text] [Related]  

  • 15. GIPR expression in gastric and duodenal neuroendocrine tumors.
    Sherman SK; Maxwell JE; Carr JC; Wang D; O'Dorisio MS; O'Dorisio TM; Howe JR
    J Surg Res; 2014 Aug; 190(2):587-93. PubMed ID: 24565507
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Somatostatin analogues inhibit cancer cell proliferation in an SSTR2-dependent manner via both cytostatic and cytotoxic pathways.
    Zou Y; Xiao X; Li Y; Zhou T
    Oncol Rep; 2009 Feb; 21(2):379-86. PubMed ID: 19148511
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Expression of somatostatin receptor subtype 2 in growth hormone-secreting pituitary adenoma and the regulation of miR-185.
    Fan X; Mao Z; He D; Liao C; Jiang X; Lei N; Hu B; Wang X; Li Z; Lin Y; Gou X; Zhu Y; Wang H
    J Endocrinol Invest; 2015 Oct; 38(10):1117-28. PubMed ID: 26036598
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bim-23244, a somatostatin receptor subtype 2- and 5-selective analog with enhanced efficacy in suppressing growth hormone (GH) from octreotide-resistant human GH-secreting adenomas.
    Saveanu A; Gunz G; Dufour H; Caron P; Fina F; Ouafik L; Culler MD; Moreau JP; Enjalbert A; Jaquet P
    J Clin Endocrinol Metab; 2001 Jan; 86(1):140-5. PubMed ID: 11231991
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Expression of somatostatin receptors in human melanoma cell lines: effect of two different somatostatin analogues, octreotide and SOM230, on cell proliferation.
    Martinez-Alonso M; Llecha N; Mayorga ME; Sorolla A; Dolcet X; Sanmartin V; Abal L; Casanova JM; Baradad M; Yeramian A; Egido R; Puig S; Vilella R; Matias-Guiu X; Marti RM
    J Int Med Res; 2009; 37(6):1813-22. PubMed ID: 20146879
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Somatostatin Analogues in the Treatment of Neuroendocrine Tumors: Past, Present and Future.
    Stueven AK; Kayser A; Wetz C; Amthauer H; Wree A; Tacke F; Wiedenmann B; Roderburg C; Jann H
    Int J Mol Sci; 2019 Jun; 20(12):. PubMed ID: 31234481
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.